14 May 2021 - Public comment period now open until 11 June 2021; requests to make oral comment during public meeting ...
11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel ...
16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...
28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient ...
22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...
12 November 2020 - Public comment period on preliminary draft now open until 11 December 2020; requests to make oral comment ...
6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...
6 November 2020 - The available evidence on the benefits of reSET-O, Connections, and DynamiCare has substantial limitations and can ...
16 October 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of vedolizumab over adalimumab. ...
16 October 2020 - Emicizumab assessed as providing comparable or better clinical benefits when compared to common current dosing levels of ...
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper ...
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels ...